Shaping your brand strategy is likely on your mind 24/7, and almost 365 days in the year. A recent case study from MDOutlook reviews how a focused approach to disease intelligence critically defines a roadmap for strategic brand decisions moving forward.

Customer

Global pharmaceutical company, currently with therapeutics in Hepato-Cellular Carcinoma (HCC).

Challenge

Client required a comprehensive overview of the patient pathways for patients diagnosed with metastatic disease in this evolving therapeutic area. Input for strategic planning and to address specific market access challenges.

Approach

• Project spanned 5 major European markets
• An in-depth literature review was combined with qualitative ThoughtLeader interviews and a quantitative online survey of over 250 HCC treaters in Europe
• Interim and final reporting

Unique Proposition MDOutlook

• Robust panel of pre-qualified and profiled treaters of HCC allowed for the required penetration in each country
• High level strategic perspective and disease knowledge went into development of discussion guides and surveys to allow for a broad review of the marketplace
• System integration of panel, survey technology and data capture allows for timely accrual

Results

• Deep insight into the current treatment landscape that involved a comprehensive look at both systemic and localized treatments
• Comprehensive patient treatment pathway maps by country and in the aggregate for EU5
• Understanding of current treatment patterns, specific to client brand and competitive treatments by disease stage, performance status and treatment setting

Value Delivered

Developed a comprehensive patient treatment pathway showing current treatment patterns in early, intermediate and advanced disease and estimation of likely future trends to guide brand building, market access and future product portfolio decisions.

Client Feedback

This is ground breaking research, as no one has comprehensively mapped out the HCC marketplace in such detail. Having your strategic guidance on what the key learnings are have helped move us forward. The reports are being circulated corporate-wide, as many departments are finding value in this research, including market access and publication planning. We have decided to use the data and results as input for a couple of scientific publications.

To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.

All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

Strategic planning is a most critical aspect of managing a product or portfolio. Often there are gaps in the internal knowledge base to make important decisions. With our institutional knowledge of oncology, proprietary access to the largest global database of cancer treaters, and hundreds of oncology intelligence projects successfully delivered, we deliver insightful and useful answers on which you can immediately build your plan.

Presenting a series of case examples, we showcase how our focused approach to disease intelligence answers your most pressing business questions in a timely manner. Learn more about our insight delivered throughout the product life cycle.

Customer

International pharmaceutical company, rapidly growing through expansion in targeted disease areas.

Challenge

Client wished to understand the current treatment paradigms in CML and the outlook for the near and long term for a portfolio investment decision. They had conducted desk research to understand the disease state, but they needed real, robust and actionable disease intelligence delivered quickly.

Approach

• 80 screened hematologists in 5 countries with a turnaround time of 2 weeks
• Customized quantitative research followed by select qualitative insights
• Consultative insights report

Unique Proposition MDOutlook

• Immediate access to pre-qualified and profiled Hematologic Oncologists
• Institutional knowledge of CML, driving timely development of survey instrument
• System integration of panel, survey technology and data capture allows for timely accrual

Results

• Actionable, relevant and deep insight into the CML treatment landscape
• Quantification of current treatment approaches and direction of future developments
• Assessment of clinical relevance of specific therapeutic characteristics

   

Value Delivered

2-Week project delivering in-depth competitive intelligence and market size modelling of current and future CML landscape. Input for “go/no-go” decision to expand portfolio in this area.

Client Feedback

This swiftly executed project provided insight that allowed us to make a quick decision based upon where the market was most likely heading. In hindsight, it was accurate about the situation as well.

To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.

All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.